Predictors of Response and Outcome to Terlipressin in Patients With Hepatorenal Syndrome

Vinit, Stéphane; Kumar, Ajay; Sharma, Prabhat; Bansal, Rinkesh Kumar; Tyagi, Pankaj; Bansal, Naresh; Singla, Vikas; Kumar, Mandhir; Ranjan, Piyush; Sachdeva, Man Updesh Singh; Arora, Amindra S.

doi:10.1016/j.cgh.2015.04.036

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Perhaps we more meaningful results would be produced if serial sampling is possible in hospitalized patients. To date, clinical factors such as serum bilirubin, early increase in arterial pressure, and the development of hypotension have been reported as predictors of the response to terlipressin [ 34 , 35 ], but favorable results have not been reported in the biomarker field.…”

Section: Discussionmentioning

confidence: 99%

The Role of Urinary N-Acetyl-β-d-glucosaminidase in Cirrhotic Patients with Acute Kidney Injury: Multicenter, Prospective Cohort Study

Yoo

Kwon

Kim

et al. 2021

JCM

View full text Add to dashboard Cite

Background and Aims: Currently, it is difficult to predict the reversibility of renal function and to discriminate renal parenchymal injury in cirrhotic patients with acute kidney injury (AKI). The aim of this study is to evaluate whether urine N-acetyl-β-D-Glucosaminidase (NAG) can predict the survival and response to terlipressin in cirrhotic patients with AKI. Methods: Two hundred sixty-two cirrhotic consecutive patients who developed AKI were prospectively enrolled from 11 tertiary medical centers in Korea between 2016 to 2019. AKI was defined as an increase in serum Cr (SCr) of 0.3 mg/dL or a 50% increase in baseline SCr. Patients diagnosed with hepatorenal syndrome (HRS-AKI) were treated with terlipressin plus albumin. Results: The patients were 58.8 ± 12.9 years old on average and were predominantly male (72.5%). The mean MELD score was 25.3 ± 9.1. When classified according to the AKI phenotype, there were 119 pre-renal, 52 acute tubular necrosis, 18 miscellaneous, and 73 HRS-AKI patients. However, the urine NAG was not effective at discriminating AKI phenotypes, except for HRS-AKI. The baseline urine NAG increased as the baseline AKI stage increased (p < 0.001). In addition, within the same AKI stage, the urine NAG values were significantly lower in the AKI-resolved group than in the unresolved group. The urine NAG level was significantly lower in living patients compared with those who died or who underwent a liver transplant within 3 months (p = 0.005). In the multivariate analysis, the increased urine NAG was a significant risk factor for the 3-month transplant-free survival (TFS) rate, especially in patients with Child–Pugh class ≤B or MELD <24. The urine NAG did not predict the response to terlipressin treatment in patients with HRS. Conclusions: Urine NAG is strongly associated with the severity of AKI in patients with liver cirrhosis and is useful for predicting the 3-month TFS.

show abstract

Section: Discussionmentioning

confidence: 99%